BioMarin Cruises While It Waits on Seventh Approval

BioMarin Pharmaceuticals (NASDAQ:BMRN) is cruising along, posting solid double-digit revenue growth in the first quarter as it waits for its seventh potential product approval for pegvaliase, which is expected from the Food and Drug Administration (FDA) on or before May 25th.